RUO: Page 3

Sysmex introduces automated analyzer for malaria detection
By LabPulse.com staff writers
The company said Plasmodium falciparum from nonfalciparum species are differentiated by the analyzer. The system can also determine the life cycle staging of the parasites detected.
September 30, 2021
2021 10 01 15 30 5893 2021 10 01 Xn 1000 Slanted Right 400
Illumina, Merck partner on HRD test
By LabPulse.com staff writers
Illumina will leverage its TruSight oncology (TSO) 500 content to develop a new HRD CDx test for the European Union and the U.K. to aid in the identification of ovarian cancer patients with positive HRD status who are eligible for treatment with Lynparza, an (ADP-ribose) polymerase inhibitor.
September 7, 2021
2019 11 15 22 54 6305 Business Hands 400
Paige and Leica form partnership
By LabPulse.com staff writers
The partnership brings together Paige's artificial intelligence research software for tumor detection, grading, and quantification and Leica Biosystems' digital pathology platform in select countries throughout North America and Europe.
April 21, 2021
2019 06 06 22 18 6673 Business Man Handshake 400
Eurofins debuts new SARS-CoV-2 variant assay
By LabPulse.com staff writers
Initiatives include sequencing more than 5,000 full genomes per day using Artic Next Generation Sequencing (NGS) and debuting NovaType, a SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) assay that identifies the SARS-CoV-2 variants B.1.1.7 and B.1.351.
January 14, 2021
2020 04 21 18 40 7882 Rna Genome 400
Qiagen debuts solution for SARS-CoV-2 T-cell research
By LabPulse.com staff writers
QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.
December 6, 2020
2019 11 19 19 30 0103 T Cell 400
Fluxergy invests $30M to produce more point-of-care SARS-CoV-2 tests
By LabPulse.com staff writers
The Fluxergy Analyzer test system, which uses polymerase chain reaction (PCR) and microfluidics technology, identified the SARS-CoV-2 virus in less than one hour during bench lab validation studies conducted by the company and in an analysis of patient samples conducted by scientists at the University of California, San Diego (UCSD).
May 12, 2020
2020 05 13 22 44 2311 Fluxergy Beta Product 400
PerkinElmer touts targeted DNA test for prenatal genetic screening
By Emily Hayes
PerkinElmer describes its Vanadis noninvasive prenatal test as a new, nonsequencing cfDNA method based on imaging and counting specific chromosome targets. The product has the CE-IVD Mark in Europe and is classified as a research use only (RUO) assay in the U.S.
August 22, 2019
2019 08 23 16 14 1200 Perkin Elmer Vanadis 20190823163612
Previous Page
Page 3 of 3